Insights Accelerated
Pause, recalibrate, execute: Advancing ATMPs in an Era of Uncertainty
As the field of Advanced Therapy Medicinal Products (ATMPs) faces mounting regulatory, financial, and scientific pressures, companies are taking a moment to pause, recalibrate, and return to execution fundamentals. This article explores how collaboration, early-stage funding, and scalable innovation are essential to ensure the continued success of next-generation therapies like cell and gene treatments.
Regulators, Rejections and the Rise of AI in U.S Drug Approval
Diamyd Medical has received FDA Fast Track and Orphan Drug Designations for its precision medicine targeting early-stage Type 1 Diabetes, now in Phase 3 trials. As the FDA begins using AI tools like Elsa, companies must craft submissions that resonate with both human and machine reviewers.
We absolutely must meet in person
While digital communication offers speed, efficiency, and global reach, it often lacks the depth, empathy, and serendipity of face-to-face interactions. In-person meetings foster trust, spark unexpected ideas, and remind us of the profoundly human elements that no screen can fully replicate.
Revolutionary Magnetic Technology Could Transform Antibody Manufacturing Economics
The biopharmaceutical industry faces challenges in efficiently manufacturing monoclonal antibodies despite their medical success. A new study shows that magnetic separation technology could significantly improve production by reducing costs, increasing output, and streamlining processes.
Interesting Times
New U.S. tariff threats on imported pharmaceuticals, particularly generics, could raise drug prices and disrupt global supply chains. While aimed at boosting domestic production, critics argue the move may have limited impact on branded drugs, risk trade tensions, and come with significant short-term costs and uncertain long-term benefits.
The Times They Are A-Changin'
Political uncertainty and shifting U.S. policies—particularly on tariffs and government funding—are creating turbulence in the life science investment climate. While long-term fundamentals remain stable, investors are cautious, and smart companies are using this period to adapt strategies and prepare for a new economic reality.
Exploring the Nordics
“May you live in interesting times” is an English expression that is claimed to be a translation of a traditional Chinese curse. The expression is intentionally ironic: "interesting" times are usually times of trouble. There is much doubt about this saying actually originating in China. There can, however, be precious little doubt that we do live in “interesting times” right now.
Power Up Your Partnering
With only a couple of weeks left to one of the life science industry’s most prominent partnering events globally, Bio International, preparations are intense among those set on taking part of this year’s edition. Between 16th and 19th of June, over 20,000 delegates are anticipated to gather in Boston for a frenzy of face2face meetings, seminars and networking events. For those new to the game, the experience could be somewhat overwhleming. Therefore, we have spoken to a couple of seasoned partnering champions, Olivier Duchamp-Giudicelli and Christina Herder, to gather some advice on how to get ahead of the game.
Client News & Events
From surgical outreach in West Africa to raising awareness about a rare esophageal disease, our clients continue to make meaningful impact around the globe. In this edition, we highlight two initiatives supported by Ventures Accelerated — one strengthening neurosurgical capacity across the African continent, and another shining a light on the daily challenges faced by those living with Eosinophilic Esophagitis (EoE).
Meet our people
Helena Strigård, Founder Ventures Accelerated
It’s been nearly two years since I set my mind on creating something like Ventures Accelerated. It was one of those pivotal moments, sitting in the garden of an old, rented house in Southern France. I had recently handed in my resignation from a job as CEO at a biologics manufacturing company and was, truthfully, a bit lost as to what the next big step would be. I had some interim gigs in the pipeline, where I had been asked to do “my thing”. But what on earth was my thing? It seemed to have something to do with driving companies or organisations past inflection points, securing their strategic positioning in the market or vis-a-vis investors. But how could I package that? And weren’t there already zillions of people doing just that ”thing”?